Design of lentivirally expressed siRNAs

Methods in Molecular Biology

Volumn 942, Issue , 2013, Pages 233-257

  Liu, Ying Poi ^a   Berkhout, Ben ^a  

^a NONE

Author keywords

AmiRNA; Gene therapy; HIV 1; Lentiviral vector; RNAi; ShRNA; SiRNA; Titer; Transduction; Viral vector

Indexed keywords

LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ARTICLE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; RNA VECTOR; TITRIMETRY;

EID: 84934437200     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-119-6_13     Document Type: Article

References (102)

1. Waterhouse PM, Wang MB, Lough T (2001) Gene silencing as an adaptive defence against viruses. Nature 411:834-842
2. Voinnet O (2001) RNA silencing as a plant immune system against viruses. Trends Genet 17:449-459
3. Wilkins C, Dishongh R, Moore SC, Whitt MA, Chow M, Machaca K (2005) RNA interference is an antiviral defence mechanism in Caenorhabditis elegans . Nature 436:1044-1047
4. Wang XH, Aliyari R, Li WX et al (2006) RNA interference directs innate immunity against viruses in adult Drosophila. Science 312: 452-454
5. Segers GC, Zhang X, Deng F, Sun Q, Nuss DL (2007) Evidence that RNA silencing functions as an antiviral defense mechanism in fungi. Proc Natl Acad Sci U S A 104:12902-12906
6. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans . Nature 391:806-811
7. Ghildiyal M, Seitz H, Horwich MD et al (2008) Endogenous siRNAs derived from transposons and mRNAs in Drosophila somatic cells. Science 320:1077-1081
8. Sijen T, Plasterk RH (2003) Transposon silencing in the Caenorhabditis elegans germ line by natural RNAi. Nature 426:310-314
9. Malone CD, Hannon GJ (2009) Small RNAs as guardians of the genome. Cell 136: 656-668
10. Yang N, Kazazian HH Jr (2006) L1 retrotransposition is suppressed by endogenously encoded small interfering RNAs in human cultured cells. Nat Struct Mol Biol 13:763-771
11. Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366
12. Nykanen A, Haley B, Zamore PD (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107:309-321
13. Zamore PD, Tuschl T, Sharp PA, Bartel DP (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33
14. Elbashir SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188-200
15. Haase AD, Jaskiewicz L, Zhang H et al (2005) TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Rep 6:961-967
16. Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W (2002) Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. EMBO J 21: 5875-5885
17. Leuschner PJ, Ameres SL, Kueng S, Martinez J (2006) Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep 7:314-320
18. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2- containing RNAi enzyme complexes. Cell 123:607-620
19. Rand TA, Petersen S, Du F, Wang X (2005) Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123:621-629
20. Hammond SM, Caudy AA, Hannon GJ (2001) Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2:110-119
21. Umbach JL, Cullen BR (2009) The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev 23:1151-1164
22. Cullen BR (2006) Is RNA interference involved in intrinsic antiviral immunity in mammals? Nat Immunol 7:563-567
23. Berkhout B, Jeang KT (2007) RISCy business: microRNAs, pathogenesis, and viruses. J Biol Chem 282:26641-26645
24. Haasnoot J, Westerhout EM, Berkhout B (2007) RNA interference against viruses: strike and counterstrike. Nat Biotechnol 25:1435-1443
25. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN (2004) The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 18:3016-3027
26. Bohnsack MT, Czaplinski K, Gorlich D (2004) Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10:185-191
27. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U (2004) Nuclear export of microRNA precursors. Science 303:95-98
28. Yi R, Qin Y, Macara IG, Cullen BR (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17:3011-3016
29. Chendrimada TP, Gregory RI, Kumaraswamy E et al (2005) TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436:740-744
30. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD (2001) A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293:834-838
31. Mourelatos Z, Dostie J, Paushkin S et al (2002) miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev 16:720-728
32. Brennecke J, Stark A, Russell RB, Cohen SM (2005) Principles of microRNA-target recognition. PLoS Biol 3:e85
33. Grimson A, Farh KK, Johnston WK, Garrett- Engele P, Lim LP, Bartel DP (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27:91-105
34. Yekta S, Shih IH, Bartel DP (2004) MicroRNA-directed cleavage of HOXB8 mRNA. Science 304:594-596
35. Krek A, Grun D, Poy MN et al (2005) Combinatorial microRNA target predictions. Nat Genet 37:495-500
36. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115:787-798
37. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R (2005) MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 7:719-723
38. Sen GL, Blau HM (2005) Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies. Nat Cell Biol 7:633-636
39. Kim DH, Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8:173-184
40. Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553
41. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16:948-958
42. Siolas D, Lerner C, Burchard J et al (2005) Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23:227-231
43. Kawasaki H, Taira K (2003) Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res 31:700-707
44. Lee Y, Kim M, Han J et al (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23:4051-4060
45. van de Wetering M, Oving I, Muncan V et al (2003) Specific inhibition of gene expression using a stably integrated, inducible smallinterfering- RNA vector. EMBO Rep 4:609-615
46. Gupta S, Schoer RA, Egan JE, Hannon GJ, Mittal V (2004) Inducible, reversible, and stable RNA interference in mammalian cells. Proc Natl Acad Sci U S A 101:1927-1932
47. Liu YP, Haasnoot J, Berkhout B (2007) Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res 35:5683-5693
48. Liu YP, von Eije KJ, Schopman NC et al (2009) Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther 17:1712-1723
49. Weinberg MS, Ely A, Barichievy S et al (2007) Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther 15:534-541
50. Saayman S, Barichievy S, Capovilla A, Morris KV, Arbuthnot P, Weinberg MS (2008) The efficacy of generating three independent anti- HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS One 3:e2602
51. Sano M, Li H, Nakanishi M, Rossi JJ (2008) Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther 16:170-177
52. Wu Z, Asokan A, Samulski RJ (2006) Adenoassociated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14:316-327
53. Kotin RM, Siniscalco M, Samulski RJ et al (1990) Site-specific integration by adenoassociated virus. Proc Natl Acad Sci U S A 87:2211-2215
54. Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA (2003) AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34:297-302
55. Russell DW (2003) AAV loves an active genome. Nat Genet 34:241-242
56. Smith RH (2008) Adeno-associated virus integration: virus versus vector. Gene Ther 15:817-822
57. Donsante A, Miller DG, Li Y et al (2007) AAV vector integration sites in mouse hepatocellular carcinoma. Science 317:477
58. Cao H, Koehler DR, Hu J (2004) Adenoviral vectors for gene replacement therapy. Viral Immunol 17:327-333
59. Buchbinder SP, Mehrotra DV, Duerr A et al (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893
60. McElrath MJ, De Rosa SC, Moodie Z et al (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905
61. O'Brien KL, Liu J, King SL et al (2009) Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15:873-875
62. Lasaro MO, Ertl HC (2009) New insights on adenovirus as vaccine vectors. Mol Ther 17:1333-1339
63. Hartman ZC, Appledorn DM, Amalfitano A (2008) Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132:1-14
64. Baum C, Schambach A, Bohne J, Galla M (2006) Retrovirus vectors: toward the plentivirus? Mol Ther 13:1050-1063
65. Hacein-Bey-Abina S, Garrigue A, Wang GP et al (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118:3132-3142
66. Mohamedali A, Moreau-Gaudry F, Richard E, Xia P, Nolta J, Malik P (2004) Selfinactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells. Mol Ther 10:249-259
67. Ellis J (2005) Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 16:1241-1246
68. Buchschacher GL Jr, Wong-Staal F (2000) Development of lentiviral vectors for gene therapy for human diseases. Blood 95:2499-2504
69. Laufs S, Guenechea G, Gonzalez-Murillo A et al (2006) Lentiviral vector integration sites in human NOD/SCID repopulating cells. J Gene Med 8:1197-1207
70. Montini E, Cesana D, Schmidt M et al (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687-696
71. Montini E, Cesana D, Schmidt M et al (2009) The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975
72. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D (2002) Germline transmission and tissuespecific expression of transgenes delivered by lentiviral vectors. Science 295:868-872
73. Pfeifer A (2004) Lentiviral transgenesis. Transgenic Res 13:513-522
74. Grimm D (2009) Small silencing RNAs: stateof- the-art. Adv Drug Deliv Rev 61:672-703
75. Grimm D, Kay MA (2007) RNAi and gene therapy: a mutual attraction. Hematol Am Soc Hematol Educ Program 1:473-481
76. Mowa MB, Crowther C, Arbuthnot P (2010) Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opin Drug Deliv 7:1373-1385
77. Raoul C, Barker SD, Aebischer P (2006) Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Ther 13:487-495
78. Stewart SA, Dykxhoorn DM, Palliser D et al (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9:493-501
79. Chen J, Wall NR, Kocher K et al (2004) Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest 113:1784-1791
80. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243-247
81. Liu YP, Berkhout B (2009) Lentiviral delivery of RNAi effectors against HIV-1. Curr Top Med Chem 9:1130-1143
82. Manjunath N, Wu H, Subramanya S, Shankar P (2009) Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 61:732-745
83. Seppen J, Rijnberg M, Cooreman MP, Oude Elferink RP (2002) Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J Hepatol 36:459-465
84. Liu YP, Haasnoot J, Ter Brake O, Berkhout B, Konstantinova P (2008) Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 36:2811-2824
85. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA (2000) A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 74:4839-4852
86. Dull T, Zufferey R, Kelly M et al (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463-8471
87. Ter Brake O, Konstantinova P, Ceylan M, Berkhout B (2006) Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 14:883-892
88. Jeeninga RE, Hoogenkamp M, Armand- Ugon M, de Baar M, Verhoef K, Berkhout B (2000) Functional differences between the long terminal repeat transcriptional promoters of HIV-1 subtypes A through G. J Virol 74:3740-3751
89. Schopman NC, Liu YP, Konstantinova P, Ter Brake O, Berkhout B (2010) Optimization of shRNA inhibitors by variation of the terminal loop sequence. Antiviral Res 86:204-211
90. Yu JY, DeRuiter SL, Turner DL (2002) RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A 99:6047-6052
91. Koper-Emde D, Herrmann L, Sandrock B, Benecke BJ (2004) RNA interference by small hairpin RNAs synthesised under control of the human 7S K RNA promoter. Biol Chem 385:791-794
92. Denti MA, Rosa A, Sthandier O, De Angelis FG, Bozzoni I (2004) A new vector, based on the PolII promoter of the U1 snRNA gene, for the expression of siRNAs in mammalian cells. Mol Ther 10:191-199
93. Ter Brake O, Thooft K, Liu YP, Centlivre M, von Eije KJ, Berkhout B (2008) Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 16:557-564
94. Haqqi T, Zhao X, Panciu A, Yadav SP (2002) Sequencing in the presence of Betaine: improvement in sequencing of the localized repeat sequence regions. J Biomol Tech 13:265-271
95. Liu YP, Vink MA, Westerink JT et al (2010) Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. RNA 16:1328-1339
96. Andersson MG, Haasnoot PCJ, Xu N, Berenjian S, Berkhout B, Akusjarvi G (2005) Suppression of RNA interference by adenovirus virus-associated RNA. J Virol 79:9556-9565
97. de Vries W, Haasnoot J, van der Velden J et al (2008) Increased virus replication in mammalian cells by blocking intracellular innate defense responses. Gene Ther 15:545-552
98. Haasnoot J, de Vries W, Geutjes EJ, Prins M, de Haan P, Berkhout B (2007) The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 3:e86
99. Popa I, Harris ME, Donello JE, Hope TJ (2002) CRM1-dependent function of a cisacting RNA export element. Mol Cell Biol 22:2057-2067
100. Higashikawa F, Chang L (2001) Kinetic analyses of stability of simple and complex retroviral vectors. Virol 280:124-131
101. Kwon YJ, Hung G, Anderson WF, Peng CA, Yu H (2003) Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis. J Virol 77: 5712-5720
102. Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K (2002) Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther 9:1155-1162